RDPAC Says Fees To Gather Phase IV Clinical Data Not Bribes
This article was originally published in PharmAsia News
RDPAC has requested to the China FDA not to consider paying doctors for collecting post-marketing phase IV clinical data as bribery, citing it as crucial for data integrity.
You may also be interested in...
A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.
The UK's MHRA is looking for manufacturers to submit COVID-19 self-tests that meet minimum and desired criteria for evaluation, after finding its recently purchased 3.5m self-tests failed to meet these standards. Criteria include no requirement for testing knowledge or training or assistance from a healthcare professional in administering or interpreting the results of the test, as well as a 95% accuracy level.
Cipla gets US FDA go-ahead earlier than anticipated for first generic of Merck’s Proventil, setting the stage for increased competition in the albuterol segment, where demand is up amid the coronavirus pandemic.